Nitrocamptothecin in Treating Patients With Metastatic Melanoma
Phase II Evaluation of RFS 2000 (9-Nitro-Camptothecin, 9NC) in Metastatic Melanoma
Sponsor: Astex Pharmaceuticals, Inc.
A PHASE2 clinical study on Melanoma (Skin), this trial is completed. The trial is conducted by Astex Pharmaceuticals, Inc. and has accumulated 6 data snapshots since 1999. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Feb 2020 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jan 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astex Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .